HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print January 13, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.1105628v1 79/4/652    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frey, A. B. Articles by Monu, N. Search for Related Content PubMed PubMed Citation Articles by Frey, A. B. Articles by Monu, N.

(Journal of Leukocyte Biology. 2006;79:652-662.)
© 2006 by Society for Leukocyte Biology

Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response

Department of Cell Biology and Kaplan Cancer Center, New York University School of Medicine, New York

¹Correspondence: Department of Cell Biology, New York University School of Medicine, 550 First Avenue, New York, NY 10016. E-mail: freya01{at}med.nyu.edu

Growth of cancer in rodent models and in patients elicits immune responses directed toward various antigens expressed by the transformed cell. Clearly though, as most tumors grow, unmanipulated antitumor immune responses are incapable of eliminating cancer. Over the past 15 years, antitumor immunoglobulin and T cells have been used to identify tumor antigens, which in turn, have served as the basis for therapeutic vaccine trials [¹ , ² ]. However, experimental cancer vaccines, although in some patients result in elimination of large tumor burdens, have a low frequency of long-term cancer remission in most patients, ca. <5% [² ]. Therefore, as tumors express antigens that distinguish themselves from nontransformed cells in immunological terms (i.e., elicit immune responses to growth of primary tumor and can target tumor cells in vivo), and tumor vaccines prime unsuccessful antitumor immune responses in patients, it is likely that growth of cancer induces immune tolerance to tumor cells. Although there are several types of T cell tolerance, mature, antigen-specific CD8⁺ T cells isolated from tumors are lytic-defective, implying that the tumor microenvironment inactivates the antitumor effector phase. The nature of the functional local tolerance to antitumor immune response is the subject of this review.

Key Words: T cells • cytolysis • tumor

This article has been cited by other articles:

				C. N. Janicki, S. R. Jenkinson, N. A. Williams, and D. J. Morgan Loss of CTL Function among High-Avidity Tumor-Specific CD8+ T Cells following Tumor Infiltration Cancer Res., April 15, 2008; 68(8): 2993 - 3000. [Abstract] [Full Text] [PDF]

				N. Monu and A. B. Frey Suppression of Proximal T Cell Receptor Signaling and Lytic Function in CD8+ Tumor-Infiltrating T Cells Cancer Res., December 1, 2007; 67(23): 11447 - 11454. [Abstract] [Full Text] [PDF]

				A. Kretz-Rommel, F. Qin, N. Dakappagari, E. P. Ravey, J. McWhirter, D. Oltean, S. Frederickson, T. Maruyama, M. A. Wild, M.-J. Nolan, et al. CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy J. Immunol., May 1, 2007; 178(9): 5595 - 5605. [Abstract] [Full Text] [PDF]

				I. Barjaktarevic, A. Rahman, S. Radoja, B. Bogunovic, A. Vollmer, S. Vukmanovic, and M. Maric Inhibitory Role of IFN-{gamma}-Inducible Lysosomal Thiol Reductase in T Cell Activation J. Immunol., October 1, 2006; 177(7): 4369 - 4375. [Abstract] [Full Text] [PDF]